Medication therapy for social phobia
Marshall, R.D.; Schneier, F.R.; Fallon, B.A.; Feerick, J.; Liebowitz, M.R.
Journal of Clinical Psychiatry 55(Suppl): 33-37
1994
ISSN/ISBN: 0160-6689 PMID: 8077172 Document Number: 438806
Social phobia, though the third most common psychiatric disorder in the United States, has received little systematic attention until recently. Chronic and disabling symptoms usually precede other disorders in individuals with comorbidity, including alcohol abuse. Though about 80% of individuals do not seek treatment, controlled trials have demonstrated efficacy for several medications, of which phenelzine (an irreversible monoamine oxidase inhibitor (MAOI)) is the best studied. The benzodiazepines, clonazepam and alprazolam, also hold promise. New reversible MAOIs such as moclobemide and brofaromine are under investigation; fluoxetine and other serotonin selective reuptake inhibitors need further controlled study. The benefits of group cognitive-behavioral therapy also appear substantial. Issues for future investigation include long-term outcome, differential therapeutics, diagnostic subtyping, and combination treatments.